Galecto Inc
NASDAQ:GLTO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Galecto Inc
EPS (Diluted)
Galecto Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galecto Inc
NASDAQ:GLTO
|
EPS (Diluted)
-$18
|
CAGR 3-Years
-108%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
EPS (Diluted)
kr15
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
EPS (Diluted)
kr91
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
EPS (Diluted)
-€3
|
CAGR 3-Years
29%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-10%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
EPS (Diluted)
kr17
|
CAGR 3-Years
N/A
|
CAGR 5-Years
28%
|
CAGR 10-Years
27%
|
|
|
Saniona AB
STO:SANION
|
EPS (Diluted)
kr2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Galecto Inc
Glance View
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. The firm is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.
See Also
What is Galecto Inc's EPS (Diluted)?
EPS (Diluted)
-18.5
USD
Based on the financial report for Dec 31, 2024, Galecto Inc's EPS (Diluted) amounts to -18.5 USD.
What is Galecto Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-61%
Over the last year, the EPS (Diluted) growth was 49%. The average annual EPS (Diluted) growth rates for Galecto Inc have been -108% over the past three years , -61% over the past five years .
